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Abstract Infections with several members of the human her-
pesviruses are the cause of significant ocular morbidity. Of the human
herpesviruses, HSV-1 is the most frequent cause of primary and recur-
rent eye disease. Despite the availability of effective antiviral treat-
ment, recurrent HSV-1 infection continues to be the leading cause of
corneal blindness in industrialized nations. This review recapitulates
the current insights in the role of the virus and the intra-corneal T 
cell response involved in the pathogenesis of human HSV-1-induced 
keratitis.
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Human herpesviruses
morphology and classification Virions of Herpesviridae
family have a characteristic morphology. An icosadeltahedral capsid
surrounds an electron opaque core in which double stranded DNA 
is located. The capsid itself is surrounded by a tegument and a viral
envelope. The viral envelope is the outer surface of the virion in 
which virus-encoded glycoproteins, exhibited as spikes, are embedded
(Fig. 1).
The overall size of the virions varies from 120–300nm. The double
stranded DNA genome ranges from 120 to 230 kilo base pairs (kb).1
The genome of herpes simplex virus (HSV) or human herpesvirus type
1 (HHV-1), the prototype of the Alphaherpesvirinae, has a unique
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Fig. 1. The morphology of herpesviruses.
a. schematic representation of the herpesvirion. Viral DNA is wrapped around a protein core that lies within a
icosadeltahedral capsid. Together these form the nucleocapsid. The tegument, an amorphous protein structure, lies between
the outer phospholipoprotein membrane and the nucleocapsid. (reprinted with permission from Pavan-Langston, Dunkel E.
Varicella Zoster virus diseases: Anterior segment of the eye. In: Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular
infection and immunity. St Louis: Mosby-Year Book; 1996. p 934).
b. Electron Micrograph of the capsid of HSV.
c. EM of the nucleus of a human corneal keratocyte with multiple herpes simplex virions.
d. detail of EM c. matching the schematic representation of the virion in a.
organization (Fig. 2). It consists of long double stranded linear mole-
cules with several repeated and inverted sequences. The DNA has two
stretches of unique sequences, one long (unique long sequence, UL) and
one that is much shorter (unique short sequence, US).2,3 Each of these
long sequences is bracketed by shorter identical DNA repeats.The viral
DNA contains terminal and internal reiterated sequences. Because of
the variability in the number of these reiterations, the size of individ-
ual genomes may vary by more than 10kb.1 The genome of her-
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Fig. 2. Schematic representation of
the arrangement of DNA sequences
in the HSV genome.2
The unique sequences (thin lines)
are flanked by the inverted repeats
boxes. Letters above the line
designate: al = terminal a sequence of
the unique long component, an =
variable number of additional a
sequences, b = the b sequence, UL =
the unique sequence of the L
component, b¢ = the repetitions of
the b sequence, am = a variable
number of a sequences, c¢ = the
inverted c sequence, US = the unique
sequence of the S component, c =
the repetition of the c sequence, as =
the terminal a sequence.
pesviruses encodes about 80 proteins. These proteins have regulatory
functions, (e.g. DNA polymerase), or are structural proteins, (e.g. gly-
coproteins).3 The glycoproteins mediate attachment of the virus to cells,
the capsid acts as a vector for the viral DNA,4 and several tegument
proteins are involved in the initiation of viral replication.3 Both glyco-
proteins and structural proteins have been shown to play a role in the
adaptive host immune responses.4,5
The family Herpesviridae comprises a group of ancient large DNA
viruses that are widespread in the animal world, having mammals, fish,
birds and reptiles as their host species. They are classified into three
subfamilies a, b and g, initially primarily on basis of tissue tropism and
related pathogenesis, but to date largely on basis of DNA sequence
homology.1 The characteristics of the human herpesviruses (HHV) are
listed in Table 1.
The a-herpesviruses have a relatively variable host range, a relative
short replication cycle, rapid spread in culture, efficient destruction of
infected cells and tendency to establish latent infections in neural
tissue. They include HSV-1 (HHV-1), HSV-2 (HHV-2) and varicella
zoster virus (VZV; HHV-3).
The b-herpesviruses have a restricted host range. The reproductive
cycle is long and the infection progresses slowly in culture.The infected
cells frequently become enlarged (cytomegalia). Latency is established
in lymphoreticular cells, kidneys and secretory glands. Human b-
herpesviruses include cytomegalovirus (CMV; HHV-5), HHV-6 and
HHV-7.
The g-herpesviruses have a very restricted host range. Viruses in this
group infect specific T- or B-lymphocytes, causing either a lytic or latent
infection. Human g-herpesviruses include Epstein-Barr virus (EBV;
HHV-4) and HHV-8.
replication and latency of herpes simplex virus (hsv)
HSV-1 is the prototype of the human herpesviruses. The lytic or pro-
ductive cycle of infection starts with the attachment of virus particles
to susceptible cells. This interaction requires sequential interaction
between viral membrane glycoproteins and cellular receptors. Entry 
of virus mediated by fusion of the envelope and plasma membranes
rapidly follows the initial attachment.3 Upon entry into the cell, the
capsids are transported to the nuclear pores where DNA is released
into the nucleus. Transcription of viral DNA takes place in the nucleus
in an orderly program. The earliest genes expressed are the five HSV
immediate-early genes (a-phase, 2–4 hours post-infection). They are
important in priming the cell for further gene expression and mobilis-
ing cellular transcription machinery. This phase is followed by the early
gene expression (b-phase, 5–7 hours post-infection): the expression of
a number of genes either directly or indirectly involved in genome
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Fig. 3. Schematic diagram of HSV
infection, latency and reactivation.
Part A, HSV infection and B, HSV
latency and reactivation. Figure
Reprinted with permission from:
Whitley RJ. Herpes simplex viruses.
In: Fields BN et al editors. Fields
virology, 3rd ed. Philadelphia:
Lippincott Raven Publishers 1996:
2297–2342.
replication. Upon genome replication viral structural proteins are
expressed in high abundance during the late phase (bg/g phase, timing
depends on viral DNA synthesis).Viral capsids assemble in the nucleus.
They bud through the host cell nuclear and cytoplasmic membranes,
becoming enveloped in the process. Viral proteins are synthesized in
the cytoplasm. Some of the host glycoproteins are captured during the
process and end up on the outer surface of the virion. Enveloped infec-
tious virions can either remain cell-associated and spread to other cells
via virus-mediated fusion, or can be released from the cell for reinfec-
tion. ‘Cell-to-cell’ spread has several important implications for the
pathogenesis of the disease. Diseases induced by HSV are character-
ized by local spread and progression of lesions, thereby largely evading
local immune surveillance and host mediated immune clearance.3
One of the most striking properties of all herpesviruses is their ability
to persist in an apparently inactive state for varying duration of time,
referred to as latency. The cellular site of latency appears to be differ-
ent from the primary tissue in which the lytic infection occurs. HSV
combines this property with a tendency for neurovirulence4. During
primary infection, neurons innervating the infected mucosa are
invaded by the virus. After initial infection the HSV ascends by retro-
grade axonal transport in nerve axons to the innervating sensory
ganglia,6,7 in which the virus replicates for several days. Subsequently,
one of two mutually exclusive events can occur, either viral replication
with neuronal destruction, which can result in severe neurological dev-
astation (myelitis or encephalitis), or establishment of a latent infec-
tion and neuronal survival (Fig. 3A). Latent infection is defined as a
type of persistent infection in which the viral genome is present but
infectious virus is not produced except during intermittent episodes of
reactivation. During latency little or no virus protein is synthesized,
although an untranslated virus transcript, the so-called latency associ-
ated transcript (LAT), is produced. Occasionally, latency is interrupted,
and the virus reactivates as the result of provocative stimuli.These may
include physical or emotional stress, fever, and exposure to ultraviolet
light, immune suppression, menstruation and tissue damage. As a con-
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sequence any local trauma can reactivate the virus and cause a mani-
fest infection.4 Reactivated virus travels down the sensory nerve and
spreads to and replicates in mucocutaneous epithelial cells, producing
the characteristic symptoms (Fig. 3B).4 Recurrent HSV infections pre-
dominantly occur at the site of primary infection.
Latent infections persist for life in the innervating sensory ganglia.8,9
Studies of HSV-induced skin diseases reveal that HSV-1 is isolated
principally from oro-labial lesions innervated by the trigeminal ganglia
and that HSV-2 is frequently isolated from lesions in the genital areas
innervated by sacral ganglia. However, in addition to these two major
sites, HSV can cause latent infection in other sites of spinal ganglia4. In
addition to ganglionic or neuronal latency, however, there is evidence
for persistence of HSV DNA in both the skin10 and the cornea.11,12,13
Expression of LAT, however, has not been detected in these peripheral
sites.
Recurrent HSV infections are thought to result mainly from reacti-
vation of the HSV strain (i.e. endogenous strain) acquired during
primary infection.14,15 However, genotypic analysis of HSV isolates
showed that a target organ is not immune to reinfection.16,17,18,19 The
reported frequency of reinfection, with an exogenous virus referred to
as HSV-1 superinfection, in large scale studies seems to be low.20,21,22
Recently, we have developed a new PCR method,23 based on the sta-
bility and strain-to-strain differences of reiterated sequences within the
HSV-1 genome, to genotype HSV-1 strains without viral culture. Eval-
uation of this technique showed that it provides a discrimination rate
of 92% of unrelated clinical HSV-1 isolates. Subsequent genotyping 
of sequential corneal HSV-1 isolates of 30 patients with recrudescent
HSV-1 keratitis patients demonstrated that the sequential isolates of
11 out of 30 patients were genetically different, suggesting corneal
HSV-1 superinfection in the inter-recurrence period. Furthermore,
corneal transplantation was identified as risk factor for corneal HSV-1
superinfection.24 This finding suggested the possibility of donor-to-host
transmission of HSV-1 through corneal grafting.
ocular manifestations of human herpesvirus infections
(table 1) The pattern of clinical disease resulting from primary
infection with human herpesviruses is largely determined by the virus
involved, the portal of entry and the immune status of the host. Gen-
erally in the fully immunecompetent host both primary and recurrent
infections cause mild or no symptoms.4 When clinical symptoms do
occur, they range from the common fever blisters on the lip to more
rare and severe infections of the central nervous system. An overview
of clinical manifestations of HHV infections is given in Tables 1 and 2
and Figure 4. Immunecompromised persons, e.g. transplant recipients,
neonates and AIDS patients, are at increased risk for severe her-
pesvirus infections.
Of the eight human herpesviruses identified to date seven have been
shown to have clinical implications for ocular infection. HSV-1 and
VZV are the viruses that cause eye disease most frequently.25,26 Not
only the eye proper, may be affected, also infections of the adnexae,
Human HSV keratitis 259
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Fig. 4. Presentations of herpes
simplex virus infections of the
anterior eye segment.
Adapted from: Sundmacher R. A
clinico-virologic classification of
herpetic anterior segment diseases
with special reference to intra-ocular
herpes. In herpetische Augen
Erkrnakungen DOG 1980. Eds R.
Sundmacher. München: JF bergmann
verlag 1981:206.
like the eyelid skin and lacrimal gland, as well as infections of the
cranial nerves27 are possible. HSV-2 infections of the eye are relatively
rare, with clinical manifestations identical to those of HSV-1.
Primary and recurrent HSV infections in immunecompetent patients
predominantly present with vesicular or ulcerating lesions on skin or
mucous membranes. The mouth and lips are the most common sites 
of HSV-1 infection. Reactivation of herpesviruses is common in the
immunecompromised host, usually resulting in asymptomatic viral
shedding or in progressive mucocutaneous infection. HSV can dissemi-
nate and cause diffuse visceral infection.28 Varicella, caused by primary
infection with VZV, is a common childhood infection. Ocular involve-
ment in varicella frequently occurs on the eyelids, whereas corneal
involvement is uncommon. Recurrent VZV infection (herpes zoster)
presents as a cluster of vesicular lesions, so-called shingles, which appear
unilaterally in the dermatomal distribution of one or more adjacent
sensory nerves.29 Herpes zoster ophthalmicus is a clinical syndrome
involving the ophthalmic branch of the trigeminal nerve. Ocular 
complications occur in 50–72% of patients with herpes zoster 
Human HSV keratitis 261
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ophthalmicus.30 In case of VZV infections of the eye the same clinical
manifestations as in HSV-1 infections are possible. In addition to these
manifestations, postherpetic neuralgia and cranial nerve palsies may
occur.31 Ocular disease caused by the reactivation of latent VZV is more
likely to occur in the elderly and the immune compromised.32,33,34,35
EBV is the most common etiologic agent of infectious mononucleo-
sis.36 EBV is also associated with malignant disease, including different
types of lymphomas and nasopharyngeal carcinoma.36,37 Ocular mani-
festations occur rarely in EBV infection. When present, they may
encompass a wide range of clinical pictures, including infections of the
anterior segment of the eye,38 neuro-ophthalmological syndromes39 and
intra-ocular lymphoma.40
Congenital infections with CMV primarily affect the reticulo-
endothelial system and the central nervous system (CNS), whereas
acquired CMV infection in immunecompetent individuals is usually
asymptomatic. Some patients, however, develop a syndrome resem-
bling infectious mononucleosis. Progression to invasive organ disease
is mainly seen in immunecompromised patients.41 Ocular manifesta-
tions are rarely seen in congenital CMV infections. Ocular involvement
in CMV infections in the adult population is confined to immunecom-
promised patients. In this group CMV is a common cause of retinitis.42
The more recently discovered human herpesviruses, HHV-6 and
HHV-7 have been associated with febrile illnesses and the childhood
disease, exanthema subitum.43 In immunecompromised patients the
spectrum of disease is extended to solid organ infections and bone
marrow depression.44 To date HHV-7 has not been associated with
ocular disease. Clinically manifest infections with HHV-8 are predom-
inantly seen in immunecompromised patients. This virus seems to
resemble EBV in its possible oncogenic properties.45 In isolated cases
HHV-6 and HHV-8 are associated with intraocular lymphomas.40,46
Epidemiology of HSV infections Herpesviruses do not persist
well on environmental surfaces, and infection needs direct inoculation
into areas where they can replicate. The first line of defense against the
virus is the keratin layer of the superficial epidermis, which prevents
direct access of these viruses to cell-membranes. In the absence of
keratin, for instance in mucous membranes, cells are more prone to be
infected.47 HSV-1 can be transmitted following close contact with the
secretions, skin, or mucous membranes of a person shedding virus.
Infection occurs via the mucosal surfaces. Infections with HSV-2 are
usually acquired through sexual contact.
Humans are considered to be the only natural reservoir of HSV. HSV
infects its host generally in the first decades of life.4 Primary infections
with HSV manifest clinically only in 1–6% of the time48 and most
episodes of clinical disease are manifestations of reactivation of HSV
infection. Because only a third of the individuals who harbor HSV rec-
ognize disease symptoms during primary or recurrent infections, sero-
logic studies are used to defining the prevalence of HSV infections in
the population. Seroprevalence rates of HSV vary with age, sex, sexual
behavior, socio-economic status and geographic location.49 In adult
populations the prevalence of HSV-1 antibodies varies from 45%50 to
262 L. Remeijer et al.
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88%.49,51,52 Corresponding with seroprevalence 70–80% of healthy indi-
viduals have HSV-1DNA in their trigeminal ganglion. There is a trend
towards a decreasing incidence of HSV-1 infections in the developed
world.49,53,54 Antibodies to HSV-2 are rarely found before ages of onset
of sexual activity. There is a trend towards an increasing incidence 
of HSV-2 infections in both the developed and developing coun-
tries.49,50,55 Although most genital HSV infections are caused by HSV-
2 infection, a recognizable and growing portion is attributable to HSV-1
infections.56
Among recipients of organ transplants, transmission of viruses
through donor tissues is a well recognized clinical problem. CMV is the
most prominent example. Manifest infection may occur, besides from
reactivation, by graft-to-host transmission of donor-derived virus as a
result of transplantation. Though rare, there are reports demonstrating
probable HSV transmission to seronegative organ transplant recipi-
ents.57,58 Corneal transplantation is the most common type of tissue
transplantation in The Netherlands. It is usually a safe procedure with
little associated morbidity. In 5–10% of these patients herpetic kera-
titis is the reason for penetrating keratoplasty (PKP).59 Herpetic 
keratitis recurs relatively frequently (10–20%) after PKP. After PKP
for reasons unrelated to HSV infection patients may still develop her-
petic keratitis in their graft,60,61,62,63 referred to as ‘newly acquired HSV
keratitis after PKP’.
epidemiology of ocular hsv-1 infection Ocular HSV infec-
tions are mainly confined to the anterior segment of the eye, including
the conjunctiva and the eyelids (Table 2). HSV appears to be the most
common infectious cause of blindness in developed countries.64 In
developing countries, where chlamydia conjunctivitis is endemic, it is
only second to trachoma as a cause of corneal blindness. In malnutri-
tion combined with measles infection, HSV keratitis is a common cause
of bilateral corneal blindness in children in the developing world.65
Despite the common exposure to HSV, ocular manifestations are only
observed in about 1% of those exposed. This may be an underestima-
tion because presenting symptoms of blepharitis and conjunctivitis are
mild, and the condition remains largely unrecognized. Only 5% of
ocular HSV disease represent primary infections.66 Liesegang et al.
reported an incidence of 8.4 first ocular HSV infections per 100,000
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Clinical manifestation Initial clinical Recurrent 
disease % disease %
Blepharitis68,69,176,177 38–54 4–20
Conjunctivitis68,69,176,177 54–84 4–20
Epithelial keratitis (dendritic)68,69,176,177 15–63 47–60
Stromal keratitis (ISK+ NSK)68,69,176,177,178 2–6 20–48
(Kerato-)uveitis 68,176 4 1
Acute retinal necrosis179 <0.00001 <0.00001
Others <0.1 <0.1
table 2. Prevalence of clinical
manifestation in individuals suffering
from ocular HSV infection.
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person-years.67 The overall prevalence of ocular HSV infection has
been estimated at 149 cases per 100,000 person-years.67
Blepharitis, conjunctivitis and epithelial keratitis are the most
common symptoms of primary ocular HSV infections. The predomi-
nant form of recurrent disease is epithelial and stromal keratitis (Table
2). Disease is bilateral in 12–19%68,69 of cases. A history of epithelial
keratitis is not a significant risk factor for recurrent epithelial keratitis,
whereas previous multiple episodes of stromal keratitis markedly
increase the probability of subsequent stromal keratitis.70 The interval
between attacks shortens with time.68 Herpetic stromal keratitis is a
leading infectious cause of blindness worldwide.67
penetrating keratoplasty (pkp) and hsv keratitis In the
general population, ocular manifestations of HSV-1 infection can lead
to unilateral blindness and as result an indication for PKP. Five to 10%
of PKPs are performed for corneal opacities resulting from HSV-1
infection.71 PKP for HSV keratitis has a high rate of post-operative
complications (Table 3). Epithelial recurrences are a major problem
after PKP. Graft rejections contribute to graft failure to a larger extent
in PKP for HSV than in PKP for reasons unrelated to HSV-1 infec-
tion.72 Recurrences of HSV keratitis after PKP and the rate of immuno-
logical graft rejection in these grafts can be reduced by antiviral
prophylaxis when steroids are employed to prevent or treat graft rejec-
tion.73 However, the use of prophylactic antiviral therapy is largely
based on experience in patients with recurrent HSV related eye disease
who have not undergone PKP.74
newly acquired corneal hsv-1 infections after pkp The
finding, that HSV-1 keratitis occurs after PKP in patients without a pre-
vious history of HSV keratitis, poses questions about the frequency and
impact of this manifestation, about the mode of transmission in these
patients, and which transplant recipients are at risk to develop this
infection.
In a retrospective analysis among 2112 patients transplanted for
reasons unrelated to HSV infection, 18 presented with HSV-1 epithe-
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Complication after PKP data for general graft failure Method
corneal transplant associated
population with HSV-1
n % n %
Newly acquired HSV-1 after 18/211275 0.9 14/25180 56 viral culture
PKP
Corneal allograft rejection 291/304871 9.5 8/17169 47 PCR
3/17169 18 GwC
Primary graft failure 215/10363181 2.1 2/3182 66 PCR
Extreme endothelial cell loss 7/120571 0.6 9/199172 4.5 PCR
in cell culture 7/199172 3.5 viral culture
table 3. Complications in corneal
allografting associated with HSV-1
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lial keratitis in their graft.75 The incidence of newly acquired HSV 
keratitis after PKP was calculated to be 1.2 per 1000 person years,
i.e.14-fold higher than that observed in the general population.76 A
recent study conducted in 25 patients with this clinical manifestation,
indicated that the majority of them (n = 14) developed severe ocular
complications resulting in social blindness of the infected eye within
three years (L. Remeijer; unpublished observation). In most cases, the
newly acquired HSV-1 infection occurs within the first two years after
PKP, again suggesting a causal relationship between corneal trans-
plantation and HSV-1 infection. Several possibilities as to the origin 
of the virus exist, such as reactivation of latent virus in the trigeminal
ganglion, viral transmission through tear shedding, viral growth in the
storage medium or transmission through the donor cornea. Infectious
agents that have been shown to be transmitted following corneal trans-
plantation include bacteria, fungi, Creutzfeldt-Jakob agent, hepatitis B
and C viruses and rabies virus.77
Transmission of HSV-1 through corneal transplantation has recently
been demonstrated by genetic characterization of HSV-1 DNA isolated
from a donor cornea before and after corneal transplantation.78 The
DNA sequences were identical for both strains. The patient proved to
be HSV-1 naive before the transplantation.
Host immune response to HSV Following a viral infection, the
immune system will recognize the virus as a foreign entity and try to
eliminate it from the host. At first, non-specific immune cells, including
macrophages, polymorphnuclear cells (PMN) and natural killer (NK)
cells, which are part of the innate immune system, are attracted to the
site of infection. Secondly, a virus-specific immune response (i.e. adap-
tive immunity) develops in which both B and T lymphocytes are
involved. This constellation of immune responses to the virus serves to
protect the infected organism from disseminated viral disease and
death.79
innate immune response The first line of defense against her-
pesviruses is formed by the innate immune system.This system consists
of cellular and soluble components. Macrophages and PMN recognize
viral antigens in a non-specific fashion and eliminate the virus by
phagocytosis and subsequent intracellular degradation. Both cell types
show a marked increase of uptake of virus when virions are opsonized
by antibody or complement.80 The anti-viral effect of NK cells involves
the lysis of viral infected cells and production of IFN-g upon stimula-
tion with other cytokines like interleukin 12 (IL-12). The recognition
of a virus-infected cell by NK cells is mediated either by the opsoniza-
tion of an infected cell by virus-specific antibody,81 or by antigen recog-
nition independently of the histocompatibility complex (MHC).82
Herpesvirus infection results in down-regulation of MHC class I mol-
ecules at the surface of an infected cell, rendering the cell susceptible
to NK cell killing.83 Low NK cell activity is linked with increased human
sensitivity to disseminated herpesvirus infections, including those with
HSV, EBV and CMV.81,82 Cells of the innate immune system are located
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in large numbers at strategic sites in and behind the physical barrier of
the organism, or circulate through the body fluids awaiting attraction
to the site of infection by chemotaxis.
The complement system and cytokines/chemokines secreted by virus
infected cells and inflammatory cells, form the major soluble com-
ponent of the innate immune response to herpesvirus infection. Viral
infection directly stimulates the production of IFN a and b by infected
cells. Both IFN a and b inhibit viral replication,84 enhance the ability
of NK cells to kill infected target cells79 and facilitate antigen process-
ing and presentation by MHC.82 The secretion of various chemokines,
like IL-8, is induced at sites of viral infection providing a chemotactic
signal for immune cells to infiltrate the affected tissue.
This first line of immune defense facilitates an immediate response
to invading infectious agents, irrespective of the site of entry. Moreover,
it will limit dissemination of the virus, while at the same time the devel-
opment of a specific immune response in the draining lymphoid tissues
is initiated to combat the remaining virus and to build up immunolog-
ical memory.
adaptive immune response Specific immune responses are
mediated by lymphocytes, recognizing the antigen by specific mem-
brane-bound antigen receptors. The adaptive immune response can be
divided into a humoral and a cellular immune response, mediated by
B and T lymphocytes, respectively.
Humoral immunity Virus-specific antibodies are important in the
defense early in the course of viral infection and in defense against
viruses that are liberated from lysed cells. Within several days after
onset of a herpesvirus infection, antibodies to some of the viral pro-
teins appear in the circulation. The major immunogens of HSV are the
viral proteins expressed at the cell surface of infected cells: the glyco-
proteins.85,86 Neutralizing virus-specific antibodies bind to envelope
proteins and prevent viral attachment and entry into host cell. Opsoniz-
ing antibodies may enhance phagocytic clearance of viral particles.
Secretory immunoglobulins of the IgA isotype, i.e. sIgA, may be impor-
tant for neutralizing viruses that enter via the mucous membranes and
trigger complement-mediated lysis of infected cells.79 Infectious cell-
free virus is mainly detected during primary infection. Herpesviruses
like HSV have a cell-to-cell spread and survive latently in the sensory
neurons, being inaccessible to antibodies after entry in the cell. In HSV
infection, antibodies do play a role in limiting dissemination the virus
from the primary site of infection to the innervating sensory ganglia
and other parts of the nervous system.87,88 Severe cases of herpesvirus
infections have been described in antibody deficiency syndromes, indi-
cating that antibodies are an important component in the immune
response to HSV infection.87
Cellular immunity Severe HSV infections in patients with impaired T
cell immunity, e.g.AIDS patients and transplant recipients, indicate that
these cells play an important role in controlling viral infection.89 Both
virus-specific CD4+ and CD8+ T cells are mandatory in controlling her-
266 L. Remeijer et al.
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pesvirus infection. They distinguish virus-infected from non-infected
cells by their T cell receptor, recognizing virus-derived peptides asso-
ciated with MHC class II or I molecules expressed at the cell surface
of infected cells, respectively.79 Following activation, T cells can kill
infected cells or secrete cytokines. Based on their cytokine production
profile, T cells can be divided into two groups: T1 and T2 cells. T1 cells
mainly secrete IL-2, IFN-g and TNF-a, whereas secretion of IL-4, IL-5
and IL-10 is restricted to T2 cells. The subgroup of T cells referred to
as T0 cells secrete both T1 and T2 cytokines. In general herpesvirus-
specific T cells responses are both T1 and T0-like.
immune evasion Herpesviruses have evolved numerous strategies
that favor their own survival by evading host immunity. These strate-
gies fall into two categories: indirect immunomodulatory effect of viral
proteins by their interaction with the protein machinery of the host cell
and the direct inhibitory effect of viral encoded proteins. Upon her-
pesvirus infection, virus-specific CD8+ T cell recognition is hampered
by the low level of MHC class I expression on infected cells. Several
herpesvirus proteins, like infected cell protein (ICP) 47 of HSV-1, have
been shown to inhibit the assembly and cell surface expression of stable
MHC class I molecules.90 Recently, ICP 22 of HSV-1 has been shown
to inhibit CD4+ T cell responses.91 Additionally, herpesviruses are able
to prevent apoptosis of infected cells.92 Some herpesviruses produce
molecules that directly inhibit innate and adaptive immune responses.
For example, human CMV encodes a protein (UL18), that inhibits T1/0
responses and is homologous to MHC class I proteins, which acts as a
decoy for NK cells93 and an EBV protein, that shows homology to IL-
10.90 Furthermore, three glycoproteins of HSV modulate the innate
immune response by binding to complement factor 3b (gC)94 or the
humoral response by binding to the Fc portion of IgG molecules
(complex of gE and gI).95
immunopathology An immunopathogenic response is an immune
response that causes tissue damage. This can occur when cells are
destroyed with a limited regenerative capacity, or when repair deposits
impair the function.96 Several mechanisms of immunopathology have
been described. A consequence of persistent infection with some
viruses is the formation of circulating immune complexes composed of
viral antigens and specific antibodies. These complexes may become
trapped in tissues and trigger inflammatory responses in which com-
plement and PMNs play a major role.96
During an immunopathogenic response the immune reaction
changes focus with time, beginning with an appropriate antiviral
response and spreading to encompass host antigens. Some viruses are
known to contain amino-acid sequences that are also present in some
self-antigens. It has been postulated that because of this ‘molecular
mimicry’ antiviral immunity can lead to immune responses against 
self-antigens. The virus antigen should be different enough from host
sequences to initiate an immune response, but similar enough that the
response is cross-reactive. The resulting ‘anti-host’ response will then
be maintained even after clearance of the virus.97 Alternatively, virus
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Fig. 5. Architecture of the human
cornea.
Photograph of a cross section of a
healthy human cornea. ep,
epithelium; B, Bowman’s layer; s,
stroma; D, Descemet’s membrane
and en, endothelium.
infection may induce autoimmunity in the absence of shared antigens,
a mechanism known as ‘bystander activation’.
Herpesvirus keratitis
corneal morphology and innervation The cornea is the
transparent tissue in the front of the eye that is primarily responsible
for focusing light on the retina. The central cornea is about 0.52mm
thick. The tissue comprises five layers: epithelium, Bowman’s layer,
stroma, Descemet’s membrane, and endothelium (Fig. 5). In the normal
state the cornea does not contain blood vessels.98
The corneal epithelium is a stratified squamous, non-keratinizing
epithelium, approximately five cell-layers thick. Epithelial cells adja-
cent to Bowman’s layer can divide and renew the epithelial layer in
two to four days. Epithelial wounds heal quickly over an intact
Bowman’s layer. The Bowman’s layer is a very thin (8–10mm) acellular
zone beneath the epithelium. Bowman’s layer is often said to be resis-
tant to trauma, offering a barrier to corneal invasion by microorgan-
isms and tumor cells, but it is not known to which extent this is true.
The Bowman’s layer is considered to have no regenerative capacity.
The stroma that constitutes about 90% of the cornea consists mainly
of collagen fibrils, ground substance and keratocytes. The collagen
fibrils of the cornea are uniform and small, about 250–300Å in diame-
ter. The ground substance surrounding the collagen fibrils is rich in gly-
cosaminoglycans. The ground substance plays a role in maintaining the
regular array of collagen fibrils. With stromal edema the individual col-
lagen fibril does not change, the volume of the ground substance
increases, and with this the space between collagen fibrils. The kerato-
cyte is the predominant cell of the stroma, but accounts only for about
5% of the dry weight of the cornea. In response to stromal injury the
keratocytes migrate into the wound area and undergo transformation
into myofibroblasts. They contribute to the scar formation by prolifer-
ation and collagen production. The Descemet’s membrane is produced
by the endothelium and approximately 10mm thick. The endothelium
is a monolayer of regularly shaped hexagonal cells, lying posterior on
268 L. Remeijer et al.
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Fig. 6. Sensory innervation of the
cornea: the subbasal nerve plexus of
the epithelium.
Nerve fiber bundles in the subbasal
plexus of the human cornea run first
in the 9 to 3 hours direction. After
the first bifurcation they run in the
12 to 6 hours direction and after the
second bifurcation they run again in
the 9 to 3 hours direction. The
beaded fibers run singly and
obliquely after branching. Reprinted
with permission from: Müller LJ, et
al. Architecture of human corneal
nerves. Invest Ophthalmol Vis Sci.
1997;38:985–994.
Descemet’s membrane. The main function of the corneal endothelium
is control of stromal hydration. This is essential for corneal trans-
parency. Endothelial cells generally do not show mitotic activity. Cell
density below a critical number (400–600 cells/mm2) is devastating for
the transparency of the cornea.98
Sensory innervation of the cornea is supplied by the ophthalmic
branch of the trigeminal nerve (ramus I, nervus V). The nerve fiber
pattern of the cornea has been described as radially oriented nerve
bundles entering the cornea from the sclera at the middle one third 
of its thickness.98 The nerves lose their myelin sheath after traver-
sing 0.5–2.0mm into the cornea and then continue as transparent 
axon cylinders. After passing Bowman’s layer, they ramify and end
within the epithelium as free nerve endings.99,100 The nerve bundles in
the subbasal plexus of the human cornea form a regular dense mesh-
work with equal density over a large central and mid-peripheral area101
(Fig. 6).
the cornea: an immune privileged site The cornea is con-
sidered to be an immune privileged tissue, in part because it cannot
directly be accessed by the immune system:102 the cornea lacks blood
and lymphatic vessels, structures that provide the conduit for trans-
portation of immunologic components into and out of most tissues.103
The absence of blood vessels leads to sequestration of corneal antigens
from the circulation. However, the normal cornea contains profes-
sional antigen presenting cells (APCs) such as dendritic cells and
macrophages.104 Factors present in the normal cornea that contribute
to immune privilege are IL-1 receptor antagonist and Fas ligand. Both
are constitutively expressed and promote ocular immune privilege by
different pathways.105,106 The cornea is in close contact with the fluid of
the anterior chamber of the eye. Several mechanisms play a role in the
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immune privilege of the anterior chamber: blood-ocular barrier, the
absence of lymphatic drainage from the intraocular structures, deviant
host immune response after introduction of antigens (aqueous
chamber associated immune deviation: ACAID) and soluble factors in
the aqueous humor having a immunosuppressive effect on APC and T
cells.107,108
Although the cornea is an immune privileged site, the complete
immune apparatus is present in the iris and at the limbus, a tissue that
constitutes the zone between the cornea and surrounding conjunctiva.
The conjunctiva has a rich lymphatic network arising approximately 
1mm peripherally from the limbus. During the course of inflammation
Langerhans’ cells (dendritic cells) migrate from the limbus into the
central cornea and the blood-ocular barrier can break down. In chronic
inflammation the cornea becomes vascularized and thus the immune
privileged state can be lost.103 Moreover, early in the inflammatory
process, leukocytes extravasate from blood vessels in the limbus and
migrate towards the center of the cornea.
Corneal HSV infections: clinical features HSV keratitis
ranges from a superficial inflammation of the cornea to a complex
ocular disease. It is usually initiated by the cytopathic effect of the virus
and followed by inflammatory responses, which may affect all layers of
the cornea. The ocular sequelae of HSV infections are determined by
the frequency and duration of the recurrent disease episodes and the
immunological response elicited. The four main categories of HSV 
keratitis109,110 are infectious epithelial keratitis (IEK), neurotrophic 
keratopathy, herpetic stromal keratitis (HSK), and endotheliitis. Each
of these is subdivided into more specific clinical presentations (See 
Fig. 4).
infectious epithelial keratitis The earliest epithelial lesions
of HSV infection in the cornea are small vesicles in the epithelium,111
which have also been described as punctate epithelial keratopathy.112
Vesicles coalesce and a branching, linear lesion with terminal bulbs
(swollen epithelial borders) develops, leading to the most common 
presentation of HSV keratitis: dendritic keratitis. The morphological
features of epithelial HSV infection are in part due to contiguous cell-
to-cell spread of the virus in the corneal epithelium restricted only by
local immune surveillance.113,114 This ‘contiguous cell-to-cell spread’,
however, does not explain the branching pattern of the dendritic
corneal lesion: an almost circular corneal lesion would theoretically
have been developed. It seems logical to postulate that HSV, with its
affinity for neural tissue, causes lesions congruent with the anatomical
pattern of innervating nerves of the target-organ. The nerve bundles in
the subbasal plexus of the human cornea form a regular dense mesh-
work with equal density over a large central and mid-peripheral area.
These nerve fiber bundles in the subbasal plexus run in the 9 to 3 hours
direction just after penetrating the Bowman’s layer, then after the first
bifurcation in the 12 to 6 hours direction and after a second bifurca-
tion again in the 9 to 3 hours direction101 (Fig. 6).The branching pattern
and the orientation of the dendritic lesion in HEK correlate with the
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anatomy of the subbasal nerve plexus in the human corneal epithe-
lium.115 In the borders of the lesion infectious virus may be present. As
the disease process continues the center ulcerates and extends through
the basement membrane.116 An enlarged dendritic ulcer, that is no
longer linear, is referred to as a geographic ulcer. Another manifesta-
tion of IEK is the marginal ulcer. The proximity of the limbus leads to
a rapid infiltration of leukocytes and neovascularization.The ulcer may
lack the typical dendritic shape.117
neurotrophic keratitis Multiple episodes of herpetic disease
can result in structural injury to the Bowman’s layer and corneal
stroma. Early findings include irregularity of corneal surface and lack
of normal luster. Punctate epitheliopathy may progress to a persistent
epithelial defect, oval shaped with smooth grayish borders.109,110
Untreated or mistreated lesions may progress into ulceration, opacifi-
cation, vascularization, and perforation of the cornea.
herpetic stromal keratitis The corneal stroma may be
affected as result of a corneal HSV infection through a variety of mech-
anisms. Stromal keratitis is a more severe and prolonged manifestation
of HSV disease and occurs when the virus initiates a chronic corneal
inflammation. It can be classified as immune stromal keratitis (ISK)
and necrotizing stromal keratitis (NSK).109,110 These two manifestations
are not mutually exclusive and probably a continuum.
Immune stromal keratitis may present as superficial stromal scarring
or the so called ‘ghost scars’, deeper located infiltrative stromal kerati-
tis. A rare form of ISK is a white ring shaped stromal lesion or the so-
called immune ring. The inflammatory response results in cellular
infiltrate, edema, neovascularization and corneal scarring as a result of
fibrosis and tissue destruction.
The predominant feature of NSK is necrosis with tissue loss, often
masked by edema in the active phase of the inflammation. The clinical
picture can evolve rather quickly and is sometimes refractory to treat-
ment. The edema and neovascularization are more pronounced com-
pared to ISK. Corneal scarring often leads to irregular astigmatism that
may strongly interfere with vision.
corneal endotheliitis Corneal endotheliitis is an inflammatory
reaction at the level of the corneal endothelium. In isolated endothe-
liitis stromal infiltrate and neovascularization are absent. Patients char-
acteristically have keratic precipitates (KP), stromal and epithelial
edema, and mild iritis. HSV endotheliitis can be classified based on the
distribution of the KP and the configuration of the overlying stromal
and epithelial edema.109 The most common form is disciform endothe-
liitis. Diffuse and linear forms of endotheliitis are also observed.118,119
When inflammation persists or is left untreated, secondary neovascu-
larization and scarring may occur. Chronic endotheliitis may lead to
endothelial decompensation.
herpes keratitis  after penetrating keratoplasty Her-
pesvirus infection in a corneal graft may present with the whole range
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of manifestations as in non-operated eyes. Early after transplantation
IEK may present as a large epithelial defect without the characteristic
dendritic appearance.120 In addition to this, herpetic keratitis might
present with the manifestations of an allograft reaction: from a linear
endotheliitis resembling a Khodadoust line119 to a diffuse endotheliitis,
indiscernible from a full blown graft rejection.120
Corneal HSV infections: diagnosis Traditionally the diagnosis
of HSV keratitis is based on history and clinical presentation, occa-
sionally complemented by viral culture. Viral isolation in cell culture
remains the standard for the detection of infectious virus. This tech-
nique is not always available in general ophthalmology practice. Viral
culture is an insensitive technique, particularly for the isolation of HSV-
1 from the deeper layers of the cornea. Cultures are only found posi-
tive in herpetic keratitis with an epithelial defect.The polymerase chain
reaction (PCR) represents a sensitive research laboratory tool and has
the advantage of detecting very small amounts of DNA or RNA. The
detection of HSV DNA by PCR provides evidence for the presence of
viral DNA, which not necessarily means the presence of infectious
virus.
Many lesions may present with a dendritic or dendriform lesion,
including the epitheliopathy seen in healing corneas after a dendritic
ulcer, a healing corneal abrasion, and the early stages of acanthamoeba
keratitis. In ISK many other causative agents of infection are possible.
However, 66% of unilateral ISK is caused by HSV.121 Other viruses
causing ISK are VZV, EBV, mumpsvirus, rubellavirus, measlesvirus and
influenzavirus. Tuberculosis, syphilis acanthamoebiasis and onchocerci-
asis are other infections associated with ISK. The complete differential
diagnosis of stromal keratitis is extensive and beyond the scope of 
this review. In severe necrotizing disease, the clinical picture can be 
suggestive of bacterial keratitis, with ulceration, dense neutrophil 
infiltration and necrosis. Differential diagnosis of unilateral corneal 
edema with a normal endothelium in the opposite eye should bring up
angle closure glaucoma and iridocorneal endothelial syndrome. When 
KPs are the only presenting sign other causes of anterior uveitis are
possible.
Additionally, HSV has been implicated in other diseases of the ante-
rior segment (Fig. 4 and table 1). HSV DNA has been detected in the
iridocorneal endothelial syndrome,122,123 in the aqueous humor during
a period of intra-ocular pressure elevation in Posner-Schlossman syn-
drome124 and in idiopathic endotheliopathy.125,126
Corneal HSV infections: pathogenesis and implications
for therapy
infectious epithelial keratitis IEK results from viral repli-
cation in corneal epithelium and destruction of corneal epithelial cells:
cytopathic effect of the virus. The duration of viral replication in the
cornea depends on viral factors, including viral load, virus strain127 and
host factors like immune status.
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The immune response in IEK consists of HSV-specific IgG and
(s)IgA present in the tear film and corneal stroma, antibody-dependent
cell-mediated cytotoxicity and HLA class I and class II restricted
immune responses.128 In addition to the specific immune reaction, IFN-
a/b production by the infected epithelial cells limits the spread of the
virus and allows resolution of the lesion. These dendritic lesions heal
without scar formation, when the epithelium is the sole tissue affected.
As the disease process continues, the infection can extend through the
basement membrane,116 into keratocytes in the superficial corneal
stroma underlying the site of the lesion resulting in HSK.129,130
In IEK topical application of antivirals accelerates the elimination of
replicating virus from the cornea.131 In this phase of the disease the
immune response is directed at limiting the spread of the virus. Inter-
ference with this immune response, for instance by corticosteroids, may
favor the spread of the virus into the stroma.132
neurotrophic keratopathy HSV-induced neurotrophic lesions
are neither infectious nor immunologic in origin. Neurotrophic ker-
atopathy is a multifactorial disease. Impaired corneal innervation in
combination with decreased tear secretion produces non-healing
epithelial defects. Basement membrane damage and stromal inflam-
mation interferes with normal epithelial wound healing.
The resulting damage should determine the therapeutic approach.
Artificial tears in dry eye syndromes, protection of a vulnerable base-
ment membrane by bandage contact lens, or low strength steroids in
chronic stromal inflammation. The keratopathy may be exacerbated by
the chronic use of topical medications, especially antiviral treatment
and toxic antibiotics.
herpetic stromal keratitis The permanent loss of vision asso-
ciated with HSV-1 corneal infection is due to an inflammatory response
in the corneal stroma.The immune response following an HSV corneal
infection resembles that observed following HSV infection at non-
ocular sites. While the immune response elicited by the infecting virus
is essential for limiting viral spread, it can have detrimental effects on
the function of the cornea.
Studies on HSK have greatly benefited from the availability of
several experimental animal models of the disease. Following inocula-
tion of HSV-1 on a scarified mouse cornea, the animal develops a
delayed onset of corneal inflammation, a non-necrotizing form of HSK,
that resembles many of the characteristics of recurrent ISK in
humans.133,134 The only human specimens of active inflammation are
those from necrotizing stromal keratitis. In immune stromal disease
transplantation is preferably performed after inflammation has 
subsided.
Key events in the development of HSK involve the interaction
between cornea infiltrating inflammatory cells and resident corneal
cells. This interaction, in which macrophages producing IL-1 and TNF-
a, and IFN-g producing Th1 cells play a pivotal role, results in the local
secretion of immune-modulatory factors including various chemokines.
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HSK in the mouse is characterized by a bi-phasic cellular infiltrate of
mainly neutrophils into the stromal layer. The first wave of neutrophils
invading the cornea is only transient and is involved in viral clear-
ance,135,136 whereas the second wave of neutrophils infiltration coincides
with clinical manifestations of the disease. These neutrophils produce
proteolytic enzymes, resulting in surrounding cell lysis and are proba-
bly responsible for most of the tissue damage.130 An essential factor for
the development of HSK is the involvement of cornea infiltrating CD4+
cells with a Th1 phenotype.137 These cells orchestrate the extravasation
and activation of infiltrating neutrophils during the clinical phase of the
disease.138,139,140,141,142 Neutrophils are known to secrete several other
chemokines with possible antiviral function like IFN-a, and TNF-a and
nitric oxide.143 Production of Th2 cytokines, such as IL-10 and IL-4,
detected in mouse corneas during the resolution phase, has been shown
to inhibit HSK.144
The Th1-derived cytokine IL-17 has been shown to play an impor-
tant role in several inflammatory diseases characterized by massive
infiltration of neutrophils into inflamed tissue.145 Recently, expression
of IL-17 has been detected in corneas of NSK patients and activated
intra-corneal T cell lines recovered from both ISK and NSK patients.
Furthermore, human corneal fibroblasts (HCF) constitutively express
the IL-17 receptor. IL-17 exhibited a strong synergistic effect with
TNF-a on the induction of IL-6 and IL-8 secretion by HCF. Secreted
IL-8 has a strong chemotactic effect on neutrophils. Additionally, IL-
17 enhanced TNF-a and IFN-g-induced secretion of macrophage
inflammatory protein 1a and 3a, while inhibiting the induced secretion
of RANTES.These data strongly suggest that IL-17 may play an impor-
tant role in the induction or perpetuation of the immunopatholgenic
process in human HSK by modulating the secretion of proinflamma-
tory and chemotactic factors by corneal resident fibroblasts.146
The antigen specificity of the corneal infiltrating T cells in HSK
remains a mystery. There are several partially conflicting theories on
the antigen specificity of these T cells involved in HSK as seen in exper-
imental mouse models. Recent studies have provided evidence that
HSK in the mouse represents an autoimmune response to corneal
tissue.147,148,149 HSK could be induced by CD4+ T cells directed to an
epitope derived from the HSV capsid protein UL6, which cross-reacts
with an epitope of an antigen uniquely expressed in the murine
cornea,147,148,149 so-called molecular mimicry. Another explanation for
the presence and activation of intra-corneal CD4+ T cells, is that the T
cell response results from exposure to cytokines in the infected cornea,
referred to as ‘bystander activation’.150,151
Only very few studies have addressed the antigen-specificity of
cornea infiltrating T cells in HSK patients. In contrast to the experi-
mental HSK model, replicating virus and viral antigens152,153,154 have
been demonstrated in the corneas, during the active as well as the inac-
tive phase of stromal keratitis in humans. HSV-specific T cells can be
detected in corneas of patients with both active and quiescent HSK, in
patients treated with steroids and also in HSV DNA-negative corneas.
These studies demonstrated that virus-specific T cells can reside in the
cornea for longer periods of time.155,156,157 In parallel to studies in the
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experimental HSK mouse model the role of auto-immunity in human
HSK was analyzed. In none of the T cell lines (TCLs) generated from
corneas of HSK patients, reactivity to UL6 or a soluble protein extract
of human corneas could be demonstrated. These data suggest that the
T cell response in HSK patients is directed to the initiating virus and
not to a human corneal autoantigen or HSV UL6.156
Intra-corneal TCL obtained from HSK patients contain high
numbers of HSV-specific T cells.158 Both CD4+ and CD8+ T cells are
potentially involved in the intra-corneal HSV-specific T cell response.
These data oppose results from studies performed in the experimental
HSK mouse model in which corneal infiltrating T cells are predomi-
nantly of the CD4+ subset. Furthermore, the majority of the human
intra-corneal TCL showed a restricted usage of T cell receptor Vb
domains.158
Antiviral treatment in ISK is both directed at the presumed presence
of the virus and at prevention of severe reactivation of infection during
steroid therapy. Topical antivirals should be used in a therapeutic dose.
It has not been established that oral antiviral therapy is effective in
acute stromal disease. However, visual acuity improved over 6 months
in significantly more patients.159 The main indication for oral acyclovir
in ISK is prevention of recurrent disease by a long-term low dose of
acyclovir.160 Steroid therapy in stromal keratitis reduces the risk of per-
sistent or progressive stromal keratitis by 68%, and leads to a signifi-
cant shorter time to resolution.161 Steroid dosage depends on the
severity of disease. In corneal disease it is rarely necessary to use
dosages exceeding dexamethasone 0.1% six times a day. When edema
and hyperemia are resolving tapering can be started slowly.
In case of NSK, both the viral replication and the severe immune
response should be treated vigorously. Control of HSV replication
should precede attempts to modulate the immune response. Both
topical and systemic antiviral treatment should be used in high thera-
peutic doses, combined after two days with corticosteroid therapy.162
corneal endotheliitis Endotheliitis probably results from lytic
viral infection of the endothelium118,163,164 with release of infectious
virus into the aqueous.165,166,167 In addition to lytic infection of endothe-
lial cells, viral antigens may be expressed on the surface of infected
cells. Immunecompetent cells may attack the endothelium, leading to
enhanced damage. This process is probably analogous to the cellular
immune response in ISK. Histopathologic studies in patients with acute
endotheliitis are missing. The immune response is deleterious to the
eye because the endothelium has no regenerative capacity. Endothelial
dysfunction leads to stromal and epithelial edema. Treatment is similar
to immune stromal keratitis.
Summarizing discussion The finding, that HSV-1 keratitis
occurs after PKP in patients without a previous history of HSV ker-
atitis,75 raises questions about the frequency and impact of this mani-
festation, about the mode of transmission in these patients, and about
the numbers of transplant recipients at risk to develop this inflamma-
tory disease. It is assumed that recurrent herpetic lesions are due to
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